Replies to post #131169 on Biotech Values

[jq1234]

I definitely agree MDV3100's theoretical advantage over Zytiga. However, I do think market gives fair valuation to MDVN currently - need to see full data.

In addition, Charles Sawyer founded Aragon two years ago to develope ARN509, similar but supposely better version of MDV3100.

http://www.aragonpharm.com/programs/arn509.htm